LYRA vs. ZYXI, RBOT, ECOR, MODD, DRIO, PETV, MLSS, POCI, STRR, and NRXS
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Zynex (ZYXI), Vicarious Surgical (RBOT), electroCore (ECOR), Modular Medical (MODD), DarioHealth (DRIO), PetVivo (PETV), Milestone Scientific (MLSS), Precision Optics (POCI), Star Equity (STRR), and NeurAxis (NRXS). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs. Its Competitors
Zynex (NASDAQ:ZYXI) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
In the previous week, Zynex had 3 more articles in the media than Lyra Therapeutics. MarketBeat recorded 4 mentions for Zynex and 1 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.75 beat Zynex's score of 0.58 indicating that Lyra Therapeutics is being referred to more favorably in the news media.
Zynex presently has a consensus target price of $4.90, indicating a potential upside of 253.79%. Lyra Therapeutics has a consensus target price of $100.00, indicating a potential upside of 1,231.56%. Given Lyra Therapeutics' higher possible upside, analysts plainly believe Lyra Therapeutics is more favorable than Zynex.
Zynex has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.
Zynex has a net margin of -19.79% compared to Lyra Therapeutics' net margin of -5,043.64%. Zynex's return on equity of -78.54% beat Lyra Therapeutics' return on equity.
Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
29.7% of Zynex shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 49.3% of Zynex shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Zynex beats Lyra Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 10/16/2025 by MarketBeat.com Staff
